---
audienceLevel: patient
cancerTypes:
- general
citation: NCI, 2025
language: en
lastReviewed: '2025-12-30'
license: public_domain
reviewFrequency: quarterly
source: NCI
sourceType: 02_nci_core
status: active
tags:
- treatment
title: Obinutuzumab - NCI
url: https://www.cancer.gov/about-cancer/treatment/drugs/obinutuzumab
version: v1
---

# Obinutuzumab - NCI

# Obinutuzumab

Placeholder slot

(OH-bin-yoo-TOO-zoo-mab)

This page contains brief information about obinutuzumab
and a collection of links to more information about the use of
this drug, research results, and ongoing clinical trials.

US Brand Name(s)

Gazyva

FDA Approved

Yes

[FDA label information for this drug is available at DailyMed.](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=df12ceb2-5b4b-4ab5-a317-2a36bf2a3cda&audience=consumer)

## Use in Cancer

Obinutuzumab
is approved
to be used with other [drugs](/Common/PopUps/popDefinition.aspx?id=348921&version=Patient&language=English) to treat:

- **[Chronic lymphocytic leukemia](/Common/PopUps/popDefinition.aspx?id=44846&version=Patient&language=English)** (CLL). It is used with [chlorambucil](/Common/PopUps/popDefinition.aspx?id=46048&version=Patient&language=English) in patients who have not yet been treated for CLL.
- **[Follicular lymphoma](/Common/PopUps/popDefinition.aspx?id=428287&version=Patient&language=English).** It is used:
- With [bendamustine hydrochloride](/Common/PopUps/popDefinition.aspx?id=386197&version=Patient&language=English) and then by itself to treat follicular lymphoma that [relapsed](/Common/PopUps/popDefinition.aspx?id=45866&version=Patient&language=English) after treatment with [rituximab](/Common/PopUps/popDefinition.aspx?id=45525&version=Patient&language=English) or did not [respond](/Common/PopUps/popDefinition.aspx?id=44085&version=Patient&language=English) to the treatment.
- With [chemotherapy](/Common/PopUps/popDefinition.aspx?id=45214&version=Patient&language=English) as [first-line treatment](/Common/PopUps/popDefinition.aspx?id=346494&version=Patient&language=English) in adults with stage II bulky, stage III, or stage IV follicular lymphoma. Patients who have at least a [partial remission](/Common/PopUps/popDefinition.aspx?id=45818&version=Patient&language=English) are then treated with obinutuzumab by itself.

Obinutuzumab
is also being studied in the treatment of other types of
[cancer](/Common/PopUps/popDefinition.aspx?id=45333&version=Patient&language=English).

## More About Obinutuzumab

[Definition from the NCI Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/570643) - Detailed scientific definition and other names for this drug.

MedlinePlus Information on [Obinutuzumab](https://medlineplus.gov/druginfo/meds/a614012.html) - A lay language summary of important information about this drug that may include the following:

- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

## Research Results and Related Resources

[Targeted Cancer Therapies](https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies)

[Monoclonal Antibodies](https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/monoclonal-antibodies)

## Clinical Trials Accepting Patients

[Find Clinical Trials for Obinutuzumab](https://www.cancer.gov/research/participate/clinical-trials/intervention/C70741) - Check for trials from NCI's list of cancer clinical trials now accepting patients.
